Neutral impactSector
Pharma revenue growth to accelerate to 11-13% this fiscal: Crisil
BusinessLine 2 hrs ago·24 Sept 2026, 12:29 pm
Crisil has forecast that the Indian pharmaceutical sector will see its revenue growth accelerate to 11-13% for the current fiscal year. This uptick is largely driven by strong domestic demand and the continued expansion of global exports.
However, this growth comes with a key challenge. The rating agency notes that rising costs for raw materials, energy, and freight are expected to squeeze profit margins. Investors should monitor how companies manage these input costs to maintain their bottom lines.
Moving forward, the focus will be on pricing power and operational efficiency. Companies that can successfully navigate these cost pressures are likely to perform better in the market.
Excerpt from BusinessLine
Indian pharma revenue growth is expected to accelerate to 11-13 per cent this fiscal from 8 per cent last year, driven by a 14-16 per cent rise in exports as drugmakers expand beyond the US into Europe, Asia, Africa and Latin America, ratings agency Crisil has said. The report said higher raw material, energy and…Read the original at BusinessLine
Key takeaways
- Category: Sector.
- Assessed as a significant, market-relevant update.
Why it matters
A meaningful update worth tracking. Use the price and stock snapshot to gauge how the market is responding.
